Myriad Genetics is continuing to legally duke it out with some of its competitors in breast and ovarian cancer genetic testing, but it is appearing increasingly likely that it will have to accept that the space will be crowded for the foreseeable future. A federal appeals court in Utah ruled in December that three patents…
After Another Legal Setback on BRCA Testing, Myriad Considers Other Options
Myriad Genetics is continuing to legally duke it out with some of its competitors in breast and ovarian cancer genetic testing, but it is appearing increasingly likely that it will have to accept that the space will be crowded for the foreseeable future. A federal appeals court in Utah ruled in December that three patents […]